<DOC>
	<DOCNO>NCT00538733</DOCNO>
	<brief_summary>Study Objectives 1 . Evaluate efficacy combination thalidomide ( Thalomid® ) , clarithromycin ( Biaxin® ) , lenalidomide ( Revlimid® ) , dexamethasone ( Decadron® ) induction therapy patient newly diagnose multiple myeloma ( MM ) . 2 . Evaluate efficacy addition thalidomide ( Thalomid® ) BiRD combination therapy therapy increase complete response rate patient newly diagnose multiple myeloma . 3 . Evaluate safety combination clarithromycin , lenalidomide , dexamethasone , thalidomide therapy patient newly diagnose MM</brief_summary>
	<brief_title>Phase II Study Thalidomide , Clarithromycin , Lenalidomide , Dexamethasone Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>This phase II study treatment program patient newly diagnose multiple myeloma . Up 25 patient enrol . Patients sign consent fulfill eligibility criterion enrol receive follow treatment plan : T-BiRD Therapy : Cycles 1-4 - Thalidomide ( 50mg daily day 1-7 , thereafter 100mg daily day 8-28 first 28 day cycle . Thalidomide give 100mg/daily day 1-28 subsequent cycle ) - Clarithromycin ( 500mg twice daily 28 day cycle ) - Lenalidomide ( 25 mg daily day 1-21 every 28 day cycle ) - Dexamethasone ( 40 mg daily day 1 , 8 , 15 22 28 day cycle ) - Prophylactic medication give . After complete 4 cycle - Patients demonstrate progression disease take study . - Patients achieve maximum response ( either achievement complete remission stable disease plateau ) transition maintenance therapy . - Patients achieve VGPR PR acceptable toxicity give T-BiRD additional 2 cycle : cycle 5 6 . Upon completion 6 cycle T-BiRD , - Patients achieve maximum response ( either achievement complete remission stable disease plateau ) transition maintenance therapy . - Patients without disease progression maximum response ( either achievement complete remission stable disease plateau ) receive BiRD therapy - Patients disease progression take study . BiRD therapy consist follow : - Clarithromycin ( 500mg twice daily 28 day cycle ) * - Lenalidomide ( 25mg daily day 1-21 every 28 day cycle ) * - Dexamethasone ( 40mg day 1 , 8 , 15 , 22 28 day cycle ) * - Prophylactic medication continue . - Patients finish T-BiRD therapy reduce dos clarithromycin , lenalidomide dexamethasone start BiRD therapy dose clarithromycin , lenalidomide dexamethasone end T-BiRD therapy . Patients progress BiRD reinitiate T-BiRD follow : - Thalidomide ( 100mg/daily day 1-28 28 day cycle ) - Clarithromycin ( 500mg twice daily 28 day cycle ) * - Lenalidomide ( 25mg/daily day 1-21 28 day cycle ) * - Dexamethasone ( 40mg day 1 , 8 , 15 , 22 28 day cycle ) * - Prophylactic medication continue - Patients continue show disease progression two cycle T-BiRD take study . - Patients finish BiRD therapy reduce dos clarithromycin , lenalidomide dexamethasone start T-BiRD therapy dose clarithromycin , lenalidomide dexamethasone end BiRD therapy . Transition maintenance therapy : Patients achieve resolution monoclonal gammopathy detect serum immunofixation achieve plateau disease ( change quantitative M-spike detect serum immunofixation ) &gt; 2 cycle either BiRD T-BiRD therapy transition maintenance therapy . Maintenance therapy comprise : - Dexamethasone 20 mg weekly ( day 1,8 , 15 , 22 28 day cycle ) * - Lenalidomide 25 mg daily day 1-21 28 day cycle . ( 15mg daily give day 1 - 21 28 day cycle patient creatinine clearance &lt; 40cc / minute ) . * - Prophylactic medication continue - Patients finish induction therapy BiRD T-BiRD reduce dos lenalidomide dexamethasone start maintenance therapy dose lenalidomide dexamethasone end induction therapy . For patient creatinine clearance &lt; 40cc / minute , lenalidomide dose low last induction therapy dose 15mg daily day 1 - 21 28 day cycle . At end every cycle ( may coincide day 1 new cycle ) , response toxicity evaluate . During cycle 1 , patient lab work do weekly ( CBC differential blood electrolyte ) female childbearing potential pregnancy test do , see APPENDIX III . All patient remain study disease progression side effect become excessive . Patients achieve stable plateau maintenance therapy define may take study eligible proceed high dose chemotherapy autologous stem cell transplantation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Subject must voluntarily sign understand write informed consent . Age &gt; 18 year time sign consent form . Histologically confirm SalmonDurie stage II III MM . Stage I MM patient eligible display poor prognostic factor ( ß2M ≥5.5 mg/L , plasma cell proliferation index ≥5 % , albumin less 3.0 , unfavorable cytogenetics ) . Newly diagnose myeloma . No antimyeloma therapy within 14 day prior initiation study treatment except corticosteroid maximum allowed dosage equivalent three pulse dexamethasone ( 40mg daily 4 day equal one pulse ) . Patients may receive adjuvant antiresorptive therapy ( i.e. , pamidronate zoledronic acid ) routine care . Measurable disease define &gt; 1.0 g/dL serum monoclonal protein , &gt; 0.1 g/dL serum free light chain , &gt; 0.2 g/24 hr urinary Mprotein excretion , and/or measurable plasmacytoma ( ) . Karnofsky performance status ≥70 % ( &gt; 60 % due bony involvement myeloma . Able take aspirin daily prophylactic anticoagulation . ( patient intolerant ASA may use warfarin low molecular weight heparin ) All study participant must register mandatory RevAssist® S.T.E.P.S.® program , willing able comply requirement RevAssist® S.T.E.P.S.® program . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide thalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . Life expectancy ≥ 3 month Subjects must meet follow laboratory parameter : Absolute neutrophil count ( ANC ) ≥1000 cells/mm3 ( 1.0 x 109/L ) Platelets count ≥ 75,000/mm3 ( 75 x 109/L ) Serum SGOT/AST &lt; 3.0 x upper limit normal ( ULN ) Serum SGPT/ALT &lt; 3.0 x upper limit normal ( ULN ) Serum creatinine &lt; 2.5 mg/dL ( 221 µmol/L ) Serum total bilirubin &lt; 2.0 mg/dL ( 34 µmol/L ) Patients nonsecretory MM ( measurable monoclonal protein , free light chain , and/or Mspike blood urine ) . Prior history malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless disease free ≥ 5 year . Myocardial infarction within 6 month prior enrollment , NYHA ( New York Hospital Association ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Pregnant lactating female ineligible . Given potential study drug trigger worsen HIV viremia incidence opportunistic infection inpatient infect HIV virus , HIV1 HIV2 positive patient exclude . The interaction HAART study drug determine . Active hepatitis B hepatitis C infection . Active viral bacterial infection coexist medical problem would significantly increase risk treatment program . Any coexist medical problem laboratory evaluation , treat physician 's principal investigator 's opinion , make patient unsuitable participate clinical trial . Known hypersensitivity dexamethasone , clarithromycin , lenalidomide , thalidomide . History thromboembolic event within past 6 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>myeloma</keyword>
	<keyword>newly diagnose multiple myeloma</keyword>
</DOC>